Preserve Access to Affordable Generics and Biosimilars Act

What happened?

Proposal in Congress

  1. Introduced in Senate
  2. Committee on the Judiciary. Ordered to be reported with an amendment in the…
  3. Committee on the Judiciary. Reported by Senator Grassley with an amendment in the…

Preserve Access to Affordable Generics and Biosimilars Act This bill prohibits parties from entering into any agreement that resolves or settles a patent claim related to…

Read the details

What this means

Status
Proposal in Congress
What happened
Preserve Access to Affordable Generics and Biosimilars Act This bill prohibits parties from entering into any agreement that resolves or settles a patent claim related to the sale of a drug or biological product and that has anticompetitive effects. Such an agreement is presumed to have anticompetitive effects if the filer of a generic drug or biosimilar application receives anything of value and agrees to limit or forego research, development, manufacturi…
What to check next
See the latest action below for the next step in Congress.
Check the original record

About this record

Preserve Access to Affordable Generics and Biosimilars Act This bill prohibits parties from entering into any agreement that resolves or settles a patent claim related to the sale of a drug or biological product and that has anticompetitive effects. Such an agreement is presumed to have anticompetitive effects if the filer of a generic drug or biosimilar application receives anything of value and agrees to limit or forego research, development, manufacturing, marketing, or sales of the generic drug or biosimilar. An agreement is exempt if the only consideration granted to the generic manufacturer is (1) the right to market and secure final approval for its product prior to the expiration of any statutory exclusivity, (2) a payment for reasonable litigation expenses, or (3) a covenant not to sue on any claim that the generic drug or biosimilar infringes a U.S. patent. An agreement is also exempt if the agreement's pro-competitive benefits outweigh the anticompetitive effects. The bill provides for enforcement by the Federal Trade Commission (FTC). Violators are subject to penalties including the forfeiture of the 180-day marketing exclusivity period for a generic drug. Additionally, when a generic or biosimilar drug manufacturer enters into an agreement with another drug manufacturer related to the manufacturing, marketing, or sale of a drug, the manufacturers must certify that the material they have given the FTC and the Department of Justice concerning the agreement contains the complete agreement and any related agreements, including descriptions of any oral agreements or representations.

Record details

Bill number
S. 1096
Congress
119
Introduced
2025-03-24
Sponsor
Sen. Klobuchar, Amy [D-MN]
Committees
Judiciary Committee
Latest documented action
Placed on Senate Legislative Calendar under General Orders. Calendar No. 46.

Documented actions

  1. Placed on Senate Legislative Calendar under General Orders. Calendar No. 46.

  2. Committee on the Judiciary. Reported by Senator Grassley with an amendment in the nature of a substitute. Without written report.

  3. Committee on the Judiciary. Reported by Senator Grassley with an amendment in the nature of a substitute. Without written report.

  4. Committee on the Judiciary. Ordered to be reported with an amendment in the nature of a substitute favorably.

  5. Read twice and referred to the Committee on the Judiciary.

  6. Introduced in Senate

Sources and related records

Source checked .